Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...

Retrovirus Life Cycles

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...

Inhibitors of Viral Protein Synthesis

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...

Subviral Agents

Subviral Agents

Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Oseltamivir drug-disease modelling in infants with influenza virus infection.

British journal of clinical pharmacology·2026

Same author

Temperature-Dependent Viral Pathogenicity: Implications for Attenuation of Viral Vaccines.

Viruses·2026

Same author

Introduction and Update: Advances in Influenza Therapeutics.

The Journal of infectious diseases·2025

Same author

Ganciclovir Dosing in Premature Infants Receiving Treatment for Congenital Cytomegalovirus Infection: Results of a Prospective Pharmacokinetic Study.

The Journal of infectious diseases·2025

Same author

EDP-323, a First-In-Class, Once-Daily, Oral L-Protein Inhibitor for the Treatment of RSV: Results From a Phase 1 Study in Healthy Adults.

Clinical and translational science·2025

Same author

Valacyclovir Pharmacokinetics in Infants With Neonatal Herpes Simplex Virus Disease.

The Pediatric infectious disease journal·2025

Search research articles

Related Experiment Video

Updated: Jul 15, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Current non-AIDS antiviral chemotherapy.

Scott T Rottinghaus¹, Richard J Whitley

¹Infectious Diseases, The University of Alabama at Birmingham, Department of Medicine, 1530 Third Avenue South, Birmingham, AL 35294-0006, USA. str@uab.edu

Expert Review of Anti-Infective Therapy

|April 4, 2007

Summary

Antiviral therapies evolved from influenza and herpes treatments to life-saving HIV/AIDS drugs. Further research is needed for other viral diseases like hepatitis and new therapies.

Area of Science:

Virology
Pharmacology
Infectious Diseases

Background:

Antiviral therapy development originated in the 1960s-1970s with influenza and herpes simplex keratitis.
Significant advancements occurred in the late 1970s-1980s, leading to treatments for herpes simplex encephalitis, herpes zoster, and genital herpes.
These breakthroughs paved the way for modern therapies, notably transforming HIV/AIDS treatment.

Purpose of the Study:

To provide a historical overview of antiviral therapy evolution.
To highlight key milestones and breakthroughs in the field.
To identify current focuses and future needs in antiviral drug development.

Main Methods:

Historical review of scientific literature and clinical developments.
Analysis of therapeutic advancements across different viral infections.

More Related Videos

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

Related Experiment Videos

Last Updated: Jul 15, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

Identification of trends in antiviral research and application.

Main Results:

Early treatments targeted influenza and herpes viruses.
Major progress in treating herpes simplex virus infections and subsequently HIV/AIDS.
Current antiviral focus includes HIV/AIDS, herpesviruses, hepatitis viruses, and influenza.

Conclusions:

Antiviral therapy has progressed significantly, offering effective treatments for several viral diseases.
Despite advances, substantial research is still required for existing targets and novel viral threats.
The development of specific therapies for a range of viral diseases remains a critical area for future research.